Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.54 |
| ▸ | SLC6A1 | P30531 | 4/20 | 0.50 |
| ▸ | FKBP1A | P62942 | 6/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.43 |
| ▸ | CPT2 | P23786 | 1/20 | 0.42 |
| ▸ | CPT1A | P50416 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL40181 | 1.00 | SIGMAR1 (0.54) | SIGMAR1SLC6A1FKBP1ASMN1; SMN2POLB | |
| SCHEMBL40124 | 0.90 | FKBP1A (0.53) | SIGMAR1FKBP1APOLB | |
| SCHEMBL40125 | 0.90 | FKBP1A (0.53) | SIGMAR1FKBP1APOLB | |
| SCHEMBL15444464 | 0.81 | SIGMAR1 (0.43) | SIGMAR1FKBP1ASMN1; SMN2 | |
| SCHEMBL15432839 | 0.81 | SIGMAR1 (0.43) | SIGMAR1FKBP1ASMN1; SMN2 | |
| SCHEMBL40126 | 0.81 | SIGMAR1 (0.52) | SIGMAR1SLC6A1FKBP1ASMN1; SMN2POLB | |
| SCHEMBL4283767 | 0.80 | HRH3 (0.56) | SIGMAR1SMN1; SMN2 | |
| SCHEMBL18734805 | 0.77 | SMN1; SMN2 (0.51) | SIGMAR1SLC6A1FKBP1ASMN1; SMN2POLB | |
| SCHEMBL19880370 | 0.77 | SMN1; SMN2 (0.51) | SIGMAR1SLC6A1FKBP1ASMN1; SMN2POLB | |
| SCHEMBL19880369 | 0.77 | SMN1; SMN2 (0.51) | SIGMAR1SLC6A1FKBP1ASMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140023611-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2014-01-23 | — | — | US | disclosed |
| EP-2591354-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | Ardelyx, Inc. (US) | 2013-05-15 | — | — | EP | disclosed |
| EP-2590656-A2 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | Ardelyx, Inc. (US) | 2013-05-15 | — | — | EP | disclosed |
| WO-2012054110-A2 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2012-04-26 | — | — | WO | disclosed |
| WO-2012054110-A2 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2012-04-26 | — | — | WO | disclosed |
| WO-2012006475-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012006475-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140023611-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC10A2, SLC34A2, SLC34A3 | SIGMAR1 1812/4885SLC6A1 41/4885FKBP1A 2199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.